SUMMARY
INTRODUCTION
HBV infection is a serious global health problem with nearly 350 -400 million individuals infected with chronic hepatitis B (CHB) worldwide [1, 2] . Approximately half of them account for MTCT or acquired in early childhood [3] . Approximately 600,000 individuals die of liver-related complications, such as acute liver failure, cirrhosis, and hepatocellular carcinoma (HCC) per year [4] . Therefore, HBV infection is a worldwide health threat, and preventing MTCT is one of the most powerful tools to decrease new HBV infections especially in Asia. Despite the use of passive-active immunoprophylaxis in infants which can effectively prevent the MTCT of HBV, 5 -10% infants of HBeAg-positive women still get HBV infections [5] . It was suggested that in these cases HBV infection of newborns occurred already in utero during pregnancy [6] . A higher maternal viral load of HBV during pregnancy seems to be a risk factor for MTCT [7] [8] [9] . Xu et al. [8] showed that maternal HBeAg positivity is an independent risk factor for MTCT as well. A large scale single-centre retrospective trial conducted by Zou et al. [9] demonstrated that vaccination failure only occurred in infants born to HBeAg-positive mothers. The study found that when maternal pre-delivery HBV DNA levels were divided into < 6, 6 -6.99, 7 -7.99, and > 8 log 10 copies/mL, the corresponding rates of vaccination failure showed a close relation to the maternal viral load. The authors found the MTCT rates in the different groups according to maternal viral load were 0%, 3.2% (3/95), 6 .7% (19/282), and 7.6% (5/66), respectively (p < 0.001). If pregnant women with HBeAg positivity and (or) high HBV DNA level use the efficient and safe anti-HBV drugs to reduce the blood titer of HBV during pregnancy, it may effectively prevent HBV vertical transmission and heighten the interruption rate of intrauterine infection. Currently, lamivudine as well as telbivudine are used during pregnancy to reduce maternal HBV load. Lamivudine treatment, analyzed earlier in two meta-analyses [10, 11] , posed a clinic evidencebased-conclusion that lamivudine can reduce the MTCT rate, and no significant higher adverse effects or complications during pregnancy were observed. A 2-year globe trial [12] and one meta-analysis [13] show that telbivudine is a potent oral nucleoside analog, demonstrating faster and superior efficacy than lamivudine in patients with HBeAg-positive CHB with less viral breakthrough and viral resistance. So telbivudine may be more effective in interrupting MTCT of HBV than lamivudine; however, no head-to-head comparison trial has been done in pregnant women yet. Piratvisuth [14] recommends telbivudine as the optimal management of HBV infection during pregnancy. Furthermore, in a large case-control study it was shown that HBIG used in the 3rd trimester in pregnant women can not effectively prevent MTCT of HBV [15] . There were only some small studies which analyzed the efficacy and safety of telbivudine for prevention of MTCT of HBV during pregnancy in high risk women. Telbivudine treatment was analyzed earlier in a metaanalysis [16] . However, the data of these studies were not conclusive. Thus we performed the meta-analysis to further address this important topic and propose an optimal management to interrupt HBV intrauterine transmission. We evaluated the efficacy of telbivudine by comparing intrauterine infection rates of infants at 6, 7, or 12 months postpartum compared to the control group (no treatment). All infants received active-passive immunoprophylaxis after birth. Additionally, we investigated the safety of telbivudine during pregnancy.
Data sources
Based on the principle and methods for Cochrane systematic reviews, a database was systematically constructed from Medline (the United State National Library of Medicine, National Institutes of Health), EMBASE, Cochrane Library, the United States National Science Digital Library (NSDL) and the China Biological Medicine Database (CBM-disc) for relevant clinical trials designed for decreasing the risk of intrauterine infection of HBV by comparing telbivudine treatment group with the no treatment group. To minimize the potential impact of published and reported bias, we performed a comprehensive keyword search for eligible studies published from November 2006 to February 2013 in English and (or) Chinese. The keywords were "telbivudine (or LdT) and hepatitis B virus (or HBV) or chronic hepatitis B or hepatitis B", "pregnant or pregnancy or mother or maternal, and newborn or infant or children or baby", and "perinatal transmission or intrauterine infection or mother-to-child transmission". The last queried date was February 3, 2013. All newborns (in both treatment and control groups) received hepatitis B immunoglobulin (HBIG) and hepatitis B virus vaccine combined immunoprophylaxis postpartum (Table 1) . We selected randomized controlled trials (RCTs) in the first place, but only found two articles relevant to RCTs in CBM-disc, one trial was excluded for design error and low quality. Other articles we found were case control studies (CCSs) published from November 2006 to May 2012, in English and Chinese ( Figure 1 ).
MATERIALS AND METHODS

Inclusion and exclusion criteria
The trials included must comply with the following standards: clear descriptive data of recruitment criteria and maternal baseline characteristics, duration and dosage of telbivudine treatment, a description of newborn and infant characteristics, a follow-up of both mothers and their babies for at least six months after delivery, and all newborns (in both treatment and control groups) received active-passive immunoprophylaxis postpartum. Mothers with other diseases or complications (such as hepatitis A, C, D, E virus, or HIV co-infection, evidence of severe liver diseases) and taking other medication during pregnancy (such as immune modulators, cytotoxic drugs or steroids) were excluded. Telbivudine (LdT, Tyzeka® in the US or Sebivo® in China) is manufactured by Novartis Pharma Stein AG, Switzerland as film-coated tablets with each tablet containing 600 mg of telbivudine. 
Data extraction and quality assessment
Two authors selected relevant studies, abstracted data, and evaluated methodological quality of trials independently. Questionable sections were resolved by discussion or consensus based on the views of a third reviewer. We contacted the authors when we encountered information that was unclear or incomplete. The trials' quality were independently assessed by two review authors using the Oxford CASP (Table 1) , a procedure to assess the methodological quality of clinical trials, scored from zero [very poor quality] to 22 [rigorous] . Potential risk bias was evaluated by the Cochrane Collaboration's tool ( Table 3 ). The following data will be extracted from the studies included: maternal HBV DNA before telbivudine treatment and prior to delivery, duration and dosage of telbivudine treatment, safety of telbivudine, and adverse effects in both mothers (such as creatine kinase elevation, intolerance to treatments, complications in pregnancy and during delivery) and their newborns (such as 1-minute Apgar score, neonatal developmental index), the prophylaxis schedule of newborns postpartum, HBsAg and HBV DNA status of newborns and infants at 6 -12 months postpartum. In the trials included, the diagnosis of HBV intrauterine infection was defined as infant peripheral blood HBsAg and (or) HBV DNA seropositive at 6 -12 months after combined active-passive immunoprophylaxis schedule.
Statistical processing
Statistical analyses were conducted by Review Manager Version 5.0 (Rev-Man 5.0) software, devised by Cochrane Collaboration. Treatment effects were indicated by 95% confidence intervals (CIs) and odds ratios (ORs). The ORs and CIs were shown in a forest plot, a graphical display designed to illustrate the relative strength of treatment effects in a number of scientific studies settling the same question. Heterogeneity of between-study statistics was assessed by Chi-square test and I2. If between-study statistics showed no heterogeneity (p > 0.1, I2 ≤ 50%), we used the Mantel-Haenszel or Inverse Variance fixed-effects model to conduct the meta-analysis. If between-study statistics showed high heterogeneity (p < 0.1, I2 > 50%), we chose either the Mantel-Haenszel or Inverse Variance random-effects model. If the sources of heterogeneity were known, subgroup analysis was introduced to decrease the heterogeneity. Publication bias was estimated by funnel plot, an asymmetric funnel was directly observed if the treatment effect of the original study was related to its sample size, suggesting the possibility of either publication bias or a systematic difference between studies or the use of an inappropriate effect measure. The stability of the results was judged by sensitivity analysis, by including or excluding some factors that affect the outcome. For all trials done, the α-level was set at 0.05 and was considered statistically difference.
RESULTS
One randomized controlled trial (RCT) [17] and six case control studies (CCSs) [18] [19] [20] [21] [22] [23] were included, including 822 HBV-carrier mothers, 454 mothers in the telbivudine treatment group, and 368 mothers in the control group (no treatment). There were 827 infants (five cases were twins), e.g., 456 infants in the telbivudine treatment group and 371 infants in the control group. For all trials done, we investigated intrauterine infection rates. According the trials included, the diagnosis of HBV intrauterine infection was defined as infant peripheral blood serum HBsAg and (or) HBV DNA seropositive at 6 -12 months postpartum after combined immunprophylaxis schedule. 95% confidence intervals (CIs) and odds ratios (ORs) demonstrated treatment efficacy. Table 4 ). The telbivudine group had 7.95 -8.25% higher anti-HBs seropositive rate (OR 23.39, CI 3.07 -178.44, p = 0.002), with minimum heterogeneity (p = 0.97, I 2 = 0%, Figure 4 ). Six trials [17, 18, [20] [21] [22] [23] provided detailed descriptions of maternal HBV DNA levels before treatment and prior to delivery in both groups (Table 5 ). There was no significant difference in maternal HBV DNA (log10) level before treatment between telbivudine treatment group and the control group (p = 0.16 for overall effect), with minimum heterogeneity (p = 0.89, I 2 = 0%, Figure 5 ). While maternal HBV DNA (log10) level prior to delivery between the two groups showed a significant difference (p < 0.001), with distinguished heterogeneity (p < 0.001, I 2 = 96%, Figure 6a ). So we introduced the Mantel-Haenszel random-effects model, sensitivity analysis (Figures 6a, 6b , and 6c), and subgroups analysis (Figure 6d) , which reduced the heterogeneity and evaluated the stability of the results. The result demonstrated, excluding trials [17, 18, 20] in which telbivudine treatment were started at 28 weeks and 28 -32 weeks of gestation, the remaining three trials [21] [22] [23] , in which telbivudine treatment started earlier between 12 -30 weeks of gestation, indicated minimum heterogeneity (p = 0.15, I 2 = 46%, Figure 6 ). Compared with the control group (Table 6) , two trials [19, 20] of the telbiv- udine treatment group had a significantly higher rate of maternal creatine kinase (CK) elevation during pregnancy (p = 0.003), with high heterogeneity (p = 0.06, I 2 = 72%, Figure 7 ), but the CK elevation had no association with muscle events. No significantly higher incidence of adverse events were observed in mothers (p = 0.89), with high heterogeneity (p = 0.1, I 2 = 64%, Figure 8 ). 
DISCUSSION
Our meta-analysis provides strong evidence that pregnant women carrying high viral loads of HBV particles are at higher risk of virus transmission to the offspring. The likelihood of transmission can be substantially reduced by treatment with telbivudine in pregnant women during the 2nd or 3rd trimester. This procedure seems to be safe for both the mother and the child.
Diagnosis of HBV intrauterine infection
Up to now, there is no consensus regarding diagnosis criteria of HBV intrauterine infection [10, [24] [25] [26] . Using a determination of the newborn's peripheral blood HBsAg-positivity within 24 hours postpartum as diagnostic criteria of intrauterine infection will overestimate the rate of intrauterine infection [5, 27] . In our analysis, the diagnosis of HBV intrauterine infection is defined as infant peripheral blood serum HBsAg and (or) HBV DNA seropositive at least 6 to 12 months postpartum [17] [18] [19] [20] [21] [22] [23] .
It is important to clarify that intrauterine transmission is not equal to MTCT. MTCT of HBV has three possible routes: intrauterine transmission, intrapartum infection, postpartum infection. Administration of hepatitis B virus vaccination and HBIG to infants born to HBsAgpositive women might block intrapartum infection and postpartum infection [6, 28] . However, there are no effective ways of treatment to interrupt intrauterine infection yet, especially in pregnant women with high HBV DNA levels and HBeAg seropositivty.
Maternal HBV DNA level
Pan et al. [29] identified the maternal serum HBV DNA level as the most important independent risk factor for MTCT. When compared with the untreated mothers, the telbivudine treatment group had a dramatic reduction of HBV DNA level. Three of the included trials had achieved 32.6% [21] , 52.8% [22] , and 30.8% [23] undetectable (< 500 copies/ mL) HBV DNA prior to delivery, whereas viral load of no treatment mothers remained unchanged and 0% of HBV DNA levels declined to undetectable. No infants of the three trials [21] [22] [23] in the telbivudine treatment group had intrauterine infection at the 7th month postpartum, compared with 7.95% [21] , 8.57% [22] , 8.25% [23] in the control groups, respectively. For all trials done, the telbivudine treatment group had a 7.95 -16.68% lower incidence of infection at 6 -12 months postpartum, indicated by infant HBV DNA seropositivity. Treatment of telbivudine during the 2nd and (or) 3rd trimesters can significantly reduce the maternal HBV DNA level and then interrupt intrauterine infection.
Safety of telbivudine
The seven trials [17] [18] [19] [20] [21] [22] [23] included in our analysis revealed no congenital deformities, no severe adverse events or complications among infants in the telbivudine treatment group during the short time of 6 -12 months of observation postpartum. Two [19, 20] of the included trials reported a higher rate (OR 7.71, 95% CI 1.99 -29.80, Figure 7 ) of creatine kinase (CK) was elevated moderately in the telbivudine treatment group during pregnancy, the majority of them were asymptomatic, and two weeks later creatine kinase returned to normal level after telbivudine withdrawal. Therefore, telbivudine treatment seems to be well tolerated and safe for pregnant women. There were no statistically significant differences between the two groups in AEs or severe adverse events (SAEs) including premature delivery, postpartum hemorrhage, premature rupture of membrane, and hepatic flare. The discontinuation of telbivudine after delivery appeared to be safe. Only mild elevation of ALT level was seen in a few mothers and none of the mothers had an increase in total bilirubin levels [21] [22] [23] .
The Food and Drug Administration (FDA) designated telbivudine as prenancy category B medication for HBV, because it was shown to have no risk to the fetus in animal model and human studies. Preclinical toxicology studies of telbivudine revealed a favorable safety, with no evidence of vital organ toxicity, genotoxicity, carcinogenicity, mitochondrial toxicity, teratogenicity, and embryo-fetal toxicity [27, 30] . Finally, it is important to note that the child's long-term safety from the use of telbivudine during pregnancy has not been established yet. More studies should be done to evaluate the long-term safety of telbivudine during pregnancy.
Prevention strategy
There is no formal guideline for prevention of intrauterine infection of HBV, but some conclusions might be reasonable. Earlier use of telbivudine during the 2nd trimester showed a lower incidence of intrauterine infection [22] . The early use of telbivudine in the 2nd trimester [21] [22] [23] showed a lower maternal HBV DNA level prior to delivery compared with the trials which started later in the 3rd trimester [17, 18, 20] . However, our metaanalysis showed that there was no significant difference between the two groups of the rate of HBV intrauterine transmission, starting telbivudine treatment at different gestational weeks and determined by HBsAg and HBV DNA at 6 -12 months postpartum, with minimum heterogeneity (p = 0.87, I2 = 0%, Figure 2 and P = 0.95, I2 = 0%, Figure 3 , respectively). Compared with the control group prior to delivery, the three trials [21] [22] [23] of the telbivudine group had higher maternal HBV DNA undetectable rate (OR 87.96, 95% CI 17.03 -454.32, p < 0.001), with minimum heterogeneity (p = 1, I2 = 0%, Figure 9 ). In the three trials [21] [22] [23] , no infants in the telbivudine treatment group had intrauterine infections. While intrauterine infection rates in the no treatment group were 9.09%, 8.57%, 8.25%, respectively, determined by infant HBsAg seropositivity 6 -12 months postpartum, and they were 7.95%, 8.57%, 8.25%, respectively, determined by infant HBV DNA seropositivity 6 -12 months postpartum. According to the antiretroviral pregnancy registry data in the antiretroviral pregnancy registry (APR) [31] and the development of anti-retroviral therapy (DART) [32] , lamivudine and tenofovir used in pregnant women with HIV and (or) HBV infections, the incidence rates of adverse outcomes showed no significant difference between the first, second, and third trimester of pregnancy. In a recent study follow-up of more than six months, telbivudine treatment in pregnant women with CHB in the entire pregnancy was safe for their babies [33] . The vital organs of the fetus developed virtually within gestational week 15 -16 and matured further in the following weeks of gestation. Based on previous studies and our meta-analysis, we suggest the use of telbivudine in pregnant women with high risk for mother to child HBV transmission in the 2nd or 3rd trimester. Furthermore, it is important that with appropriate immunoprophylaxis, breastfeeding in the mothers who are HBV carriers does not increase MTCT rate of HBV [34] . But breastfeeding is not recommended if mothers are under antiviral treatment with telbivudine and/or lamivudine [35] . Maternal hepatitis infection transmitted to the newborn might be interesting in the context of fetal programming. The 'fetal origin' hypothesis proposes that adult cardiovascular and metabolic diseases originate through adaptation of the fetus in relationship to environmental conditions in early life [36] . It was proposed that an event in a critical early period of life permanently alters organ structure and function in response to environmental factors. Such events may lead to cardiovascular/ metabolic diseases in later life. The classical event causal for fetal programming is maternal under-nutrition during pregnancy. This was first recognized in epidemiological studies and later confirmed in animal experiments [37] [38] [39] [40] . Meanwhile, several other mechanisms caused by environmental conditions in early life leading to lifelong functional and structural alterations have been described, among them glucocorticoid exposure of the fetus to 11 beta-hydroxysteroid dehydrogenase deficiency of the placenta [41, 42] or even high protein diet during pregnancy [43] . It was shown, for example, that high maternal cortisol levels during pregnancy may adversely affect the growth of the fetal brain [44] . Another mechanism responsible for programming events during intrauterine life might be related to maternal genes affecting the fetal phenotype independent of the fetal genome [45, 46] . Recent studies indicate that programming of insulin resistance may be one of the keys underlying molecular mechanisms also explaining the low birth weight phenotype [47] [48] [49] [50] . Little, however, is known about fetal programming and maternal infectious diseases as an underlying mechanism. Although it appears plausible that maternal infections may also alter placental function, thus inducing fetal programming. The opposite was recently shown: Low birth weight seems to be a risk factor for lower respiratory tract infections in children with Hand, Foot, and Mouth Disease [51] . Short-term consequences of maternal hepatitis B infection are known [52] ; however, adequately designed long-term studies are missing so far. Our work may stimulate others to address this question.
Study limitations
Although our analysis is based on the principles and methods of Cochrane systematic reviews, quality of trials rigorously assessed by Oxford CASP, further evaluated risk of bias by the Cochrane Collaboration's tool; however, the quality of some trials was still not high. Moreover, there is a lack of high quality randomized controlled trials (RCTs). Only two RCTs were found in the CBM-disc, one trial was excluded for design error and low quality, another trial did not systematically describe the sequence generation and blinding method. Lacking high quality RCTs in the meta-analysis may render a selection bias and lead to heterogeneity. We searched only published trials in English or Chinese, which might also heighten a selection bias. Publication bias should also be taken into consideration, which may exaggerate the treatment efficacy. In order to arrive at a more convincing conclusion of telbivudine efficacy in HBV intrauterine transmission, more RCTs of higher quality and larger trials are needed. It is clearly a study limitation that only few well controlled studies are available so far addressing this important topic. 
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